Neonc Technologies Holdings (NTHI) Change in Accured Expenses (2024 - 2026)
Neonc Technologies Holdings (NTHI) posted quarterly Change in Accured Expenses of -$390550.0 for Q1 2026, down 34.62% year-over-year from -$597374.8 in Q1 2025, and down 133.16% quarter-over-quarter from $1.2 million in Q4 2025.
Neonc Technologies Holdings (NTHI) Change in Accured Expenses (2024 - 2026) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported Change in Accured Expenses for 3 consecutive years, with -$390550.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 34.62% year-over-year to -$390550.0; the TTM figure through Mar 2026 stood at -$580217.0 (down 65.55% YoY), while the FY2025 annual figure was -$479775.0, down 954.74% from the prior year.
- Change in Accured Expenses slipped to -$390550.0 in Q1 2026 per NTHI's latest filing, from $1.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.4 million in Q2 2024 and bottomed at -$1.2 million in Q3 2025.
- Historically, Change in Accured Expenses has averaged -$90466.0 across 3 years, with a median of -$290108.0 in 2025.
- On a YoY basis, Change in Accured Expenses climbed as much as 230.73% in 2025 and fell as far as 349.02% in 2025.
- Neonc Technologies Holdings' Change in Accured Expenses stood at -$901031.0 in 2024, then jumped by 230.73% to $1.2 million in 2025, then slumped by 133.16% to -$390550.0 in 2026.
- Business Quant data shows NTHI's Change in Accured Expenses at -$390550.0 in Q1 2026, $1.2 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | 823,700.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 823,700.00 |
| Jun 30, 2026 | 823,700.00 |
| Mar 31, 2026 | -390,550.00 |
| Mar 31, 2026 | -390,550.00 |
| Dec 31, 2025 | 1.18 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | -189,667.00 |
| Jun 30, 2025 | -189,667.00 |
| Mar 31, 2025 | -290,108.00 |
| Mar 31, 2025 | -290,108.00 |
| Dec 31, 2024 | -901,031.00 |
| Dec 31, 2024 | -901,031.00 |
| Sep 30, 2024 | -594,110.00 |
| Sep 30, 2024 | -594,110.00 |
| Jun 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 116,500.00 |
| Mar 31, 2024 | 116,500.00 |